Evidence map›Paper›PMID 31063078›Full record

ReviewHuman vaccines & immunotherapeutics2019

Should female sex workers be offered HPV vaccination?

Maarten F Schim van der Loeff, Alex Vorsters, Elske Marra, Pierre Van Damme, Arjan Hogewoning

Open access · bronzeAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Safety and immunogenicity of anHuman vaccines & immunotherapeutics · 2022
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Letter to the editor: female sex workers and HPV vaccine.Human vaccines & immunotherapeutics · 2020
    Article
  8. Letter to the editor: female sex workers and HPV vaccine.Human vaccines & immunotherapeutics · 2020
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Maarten F Schim van der Loeffa Department of Infectious Disease, Public Health Service Amsterdam , Amsterdam , The Netherlands.
Alex Vorstersd Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerpen , Antwerp , Belgium.
Elske Marraa Department of Infectious Disease, Public Health Service Amsterdam , Amsterdam , The Netherlands.
Pierre Van Dammed Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerpen , Antwerp , Belgium.
Arjan Hogewoninga Department of Infectious Disease, Public Health Service Amsterdam , Amsterdam , The Netherlands.
Amsterdam University Medical Centers · NLUniversity of Antwerp · BEGGD Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prophylactic vaccines are efficacious in preventing Human Papillomavirus (HPV) infection and subsequent cervical intraepithelial neoplasia (CIN), cervical cancer, other anogenital cancers, and anogenital warts. Female sex workers (SW) are at increased risk of acquiring sexually transmitted infections, including HPV. There are several reasons to offer HPV vaccination to SW: they are at high risk for HPV and often unvaccinated, and the immunogenicity of the vaccine is also excellent in previously HPV exposed women. Furthermore, women with disease caused by HPV may still benefit from vaccination. The efficacy of vaccinating mid-adult women (26-44 years old) against persistent HPV infection and CIN2+ is good. Although an SW may have been infected or exposed to HPV, she may not have been exposed to all vaccine-included hrHPV types. Vaccination induces mucosal immunity via the production of neutralizing antibodies on the surface of the female genital tract, thus preventing potential transmission to clients. Nevertheless, some considerations argue against offering vaccination to SWs. Current vaccines are only prophylactic and as such, do not affect current HPV infections. Women who have previously cleared HPV infections, may do so again and thus not need vaccination. Fewer SW might be naïve to HPV-types than currently thought. HPV vaccination has probably no effect on latent infections. Vaccinating sometime after sexual debut could be too late, as infections have already occurred. Taken together, some data suggest that vaccination of SW may offer health benefits, also for the community, but sufficient evidence is lacking. In certain cases, HPV vaccination of SW may be recommended. Evidence-based, public health decisions concerning vaccination of SW are challenging and could be facilitated with more research in this high-risk group.

Indexed as

Immunization ProgramsSex WorkersDisease Transmission, InfectiousFemaleHumansPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsPapillomavirus VaccineseffectivenessHuman Papillomavirussex workervaccine

Identifiers

PMID31063078
PMCPMC6746505
OpenAlexW2944099794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.